The Evolving Landscape of Viral, Immune, and Molecular Biomarkers in Penile Cancer.

[1]  R. Blaheta,et al.  Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer , 2022, Cancers.

[2]  M. Michaelis,et al.  Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer , 2021, Cancers.

[3]  A. Naing,et al.  Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial , 2021, Investigational New Drugs.

[4]  P. Spiess,et al.  Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. , 2021, International immunopharmacology.

[5]  M. Guo,et al.  Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma , 2021, Clinical Cancer Research.

[6]  K. Gage,et al.  Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab , 2020, Frontiers in Oncology.

[7]  P. Spiess,et al.  The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy , 2020, Journal of clinical medicine.

[8]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[9]  G. Sonpavde,et al.  Systematic Review and Meta-Analysis: Is There a Benefit in Using Neoadjuvant Systemic Chemotherapy in Locally Advanced Penile Squamous Cell Carcinoma? , 2020, The Journal of urology.

[10]  S. Kjær,et al.  Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. , 2019, The Lancet. Oncology.

[11]  H. Thygesen,et al.  The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma , 2018, Front. Immunol..

[12]  L. Mariani,et al.  First‐line therapy with dacomitinib, an orally available pan‐HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open‐label, single‐arm, single‐centre, phase 2 study , 2018, BJU international.

[13]  P. Spiess,et al.  Advances in Understanding of Penile Carcinogenesis: The Search for Actionable Targets , 2017, International journal of molecular sciences.

[14]  T. Masterson,et al.  Updates on the epidemiology and risk factors for penile cancer , 2017, Translational andrology and urology.

[15]  A. Giuliano,et al.  Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies , 2016, CA: a cancer journal for clinicians.

[16]  A. Chinnaiyan,et al.  Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  K. Stratton,et al.  A Contemporary Review of HPV and Penile Cancer. , 2016, Oncology.

[18]  Kathleen R. Cho,et al.  Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. , 2015, Cancer research.

[19]  Michael Dallas,et al.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.

[20]  S. Rosenberg,et al.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Schrader,et al.  The role of histologic subtype, p16INK4a expression, and presence of human papillomavirus DNA in penile squamous cell carcinoma , 2015, BMC Cancer.

[22]  P. Snijders,et al.  Human papillomavirus prevalence in invasive penile cancer and association with clinical outcome. , 2015, The Journal of urology.

[23]  José Vassallo,et al.  Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence , 2015, Tumor Biology.

[24]  P. Spiess,et al.  Novel targeted therapies for the treatment of penile cancer , 2014, Expert opinion on drug discovery.

[25]  G. Netto,et al.  The epidermal growth factor receptor is frequently overexpressed in penile squamous cell carcinomas: a tissue microarray and digital image analysis study of 112 cases. , 2013, Human pathology.

[26]  G. Botti,et al.  Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study , 2013, Journal of Translational Medicine.

[27]  R. Burbano,et al.  Human Papilloma Virus: Prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma. , 2013, International braz j urol : official journal of the Brazilian Society of Urology.

[28]  J. Cuzick,et al.  Alternative HER/PTEN/Akt Pathway Activation in HPV Positive and Negative Penile Carcinomas , 2011, PloS one.

[29]  J. Tomimori,et al.  Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations. , 2011, Anais brasileiros de dermatologia.

[30]  J. Pow-Sang,et al.  Epidemiology and natural history of penile cancer. , 2010, Urology.

[31]  A. Giuliano,et al.  Burden of invasive squamous cell carcinoma of the penis in the United States, 1998–2003 , 2008, Cancer.

[32]  J. Berkhof,et al.  Presence of high‐risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival , 2006, International journal of cancer.

[33]  K. Holmes,et al.  Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. , 2004, The Journal of infectious diseases.

[34]  M. von Knebel Doeberitz,et al.  Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high‐risk human papillomavirus , 2003, The Journal of pathology.

[35]  S. Serrano,et al.  p53 as a new prognostic factor for lymph node metastasis in penile carcinoma: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. , 2002, The Journal of urology.

[36]  A. Lopes,et al.  Human papillomavirus as a prognostic factor in carcinoma of the penis , 2001, Cancer.

[37]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.